Form 4: Tarsus CFO Farrow Settles Vested RSUs

Jeffrey S. Farrow, CFO and CSO of Tarsus Pharmaceuticals, settled 13,042 vested Restricted Stock Units, acquiring common stock on March 15, 2026.

Summary

• Jeffrey S. Farrow, Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc., settled vested Restricted Stock Units (RSUs).
• On March 15, 2026, Farrow acquired 13,042 shares of common stock through the settlement of these RSUs.
• This transaction involved the vesting of two RSU grants: 8,020 units from a March 7, 2024 grant and 5,022 units from a March 5, 2025 grant.
• Following these transactions, Farrow beneficially owns 49,746 shares of common stock directly.
• Farrow also holds 16,040 unvested RSUs from the March 7, 2024 grant and 15,067 unvested RSUs from the March 5, 2025 grant.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents a routine compensation action where an officer acquires company stock, aligning their interests with shareholders, without indicating any immediate operational or financial changes.

Positives

• The acquisition of common stock by a key officer through RSU settlement indicates continued equity ownership and alignment with shareholder interests.

Future Outlook

Future vesting schedules indicate that 25% of the RSUs granted on March 7, 2024, will vest annually on March 15th through 2028, and 25% of the RSUs granted on March 5, 2025, will vest annually on March 15th through 2029, contingent on continuous service.

Industry Context

StockSavvy.ai notes that RSU vesting and settlement are standard components of executive compensation packages in the biotechnology and pharmaceutical industries, designed to align management incentives with long-term shareholder value creation. This transaction reflects a routine compensation event rather than a discretionary open market purchase or sale.

Stakeholder Impact

• Shareholders: The transaction increases the officer's direct ownership, potentially strengthening alignment of interests.
• Employees: The RSU vesting schedule provides insight into the company's long-term incentive structure for key personnel.

Next Steps

• Remaining RSUs from the March 7, 2024 grant will vest 25% annually on March 15th of 2027 and 2028.
• Remaining RSUs from the March 5, 2025 grant will vest 25% annually on March 15th of 2027, 2028, and 2029.

Key Dates

Recommendation

This Form 4 filing details a routine RSU vesting and settlement for a key officer, which is an expected part of executive compensation. It does not provide new information that would fundamentally alter the investment thesis for Tarsus Pharmaceuticals, hence a 'hold' recommendation is appropriate as it maintains the status quo without new catalysts for 'buy' or 'sell'.

Keywords

Tarsus Pharmaceuticals, TARS, Jeffrey Farrow, Form 4, SEC filing, Restricted Stock Units, RSU, insider transaction, beneficial ownership, equity compensation